Creating a new adjuvant system to improve flu vaccines
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
This study is testing a new way to boost the effectiveness of flu vaccines by using a special combination of ingredients that help your immune system respond better, and it's aimed at making future flu shots work even stronger for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inimmune Corporation NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project ID | NIH-10935776 on NIH RePORTER |
What this research studies
This research focuses on developing a novel synthetic adjuvant system designed to enhance the immune response to influenza vaccines. By combining a fully synthetic TLR4 agonist with a semi-synthetic saponin, the study aims to improve the effectiveness of flu vaccines in generating strong antibody and T-cell responses. The research is currently in the pre-clinical phase, where the new adjuvant has shown promising results when tested with flu antigens. The goal is to optimize and produce this adjuvant for future clinical use.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk for influenza, including those with compromised immune systems or chronic health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received effective vaccinations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective influenza vaccines, providing better protection against seasonal flu and potentially reducing the severity of infections.
How similar studies have performed: Other research has shown success with similar adjuvant systems, indicating a promising potential for this novel approach.
Where this research is happening
Missoula, United States
- Inimmune Corporation — Missoula, United States (Active)
Researchers
- Principal investigator: Burkhart, David — Inimmune Corporation
- Study coordinator: Burkhart, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.